| Literature DB >> 31939310 |
Hsin-Pei Yeh1, Yu-Chuen Huang2,3, Li-Ying Wang4,5, Pei-Wei Shueng1,6, Hui-Ju Tien1,7, Chiu-Han Chang1, San-Fang Chou8, Chen-Hsi Hsieh1,6,9.
Abstract
OBJECTIVES: To evaluate the feasibility and optimal restricted angle of the complete-directional-complete block (CDCB) technique in helical tomotherapy (HT) by including regional nodal irradiation (RNI) with the internal mammary node (IMN) in left-sided breast cancer.Entities:
Mesh:
Year: 2020 PMID: 31939310 PMCID: PMC7362916 DOI: 10.1259/bjr.20190792
Source DB: PubMed Journal: Br J Radiol ISSN: 0007-1285 Impact factor: 3.039
The staging characteristics of the selected patients
| Patient | Stage | Without neoadjuvant treatment | Postneoadjuvant treatment | ER | PR | Her2/neu | Surgical technique | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| pT | pN | M | ypT | ypN | M | ||||||
| 1 | IIIC | 2 | 3a | 0 | - | - | - | 0% | 0% | 3+/3+ | BCT |
| 2 | IIB | 2 | 1 | 0 | - | - | - | 95% | 95% | 2+/3+ | BCT |
| 3 | IIA | 2 | 0 (i+) | 0 | - | - | - | 1% | 1% | 0/3+ | BCT |
| 4 | IIIC | 2 | 3 | 0 | - | - | - | 90% | 90% | 2+/3+ | MRM |
| 5 | IIIA | 2a | 2a | 0 | - | - | - | 0% | 0% | 3+/3+ | MRM |
| 6 | IIIC | 2 | 3 | 0 | - | - | - | 0% | 0% | 0/3+ | MRM |
| 7 | IIA | 1b | 1 | 0 | - | - | - | 0% | 0% | 0/3+ | BCT |
| 8 | ypIIA | - | - | - | from 1c to 1a | from 1 | 0 | 90% | 90% | 1+/3+ | BCT |
| 9 | ypIIB | - | - | - | from 3 | from 3a to 0 | 0 | 1% | 0% | 3+/3+ | MRM |
| 10 | ypIA | - | - | - | from 4b to 1b | from 2 | 0 | 0% | 0% | 3+/3+ | MRM |
BCT, breast-conserving surgery; MRM, modified radical mastectomy.
i+: ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph nodes.
Figure 1.The CDCB. The CB was a rectangular structure with the ends connected 3 cm away from the margin of the planning target volumes (PTV). The CB was designed to disable beamlets from entering or exiting through this structure. The directional-blocking area of the CDCB was determined by the intersection of where the CB and the beam aperture passed through the 0.5 cm margin of the PTV of the IMNs. Directional block was used to close the beamlets if the blocked structure was proximal to the target in order to limit the beamlet entrance direction. The CDCB restricts the beamlets to enter within limited angles, and beam angles of 0, 10, 15 and 20 degrees were used as the restricted angles according to the geometric center of the IMNs (in the first to third interspaces) and were used to determine the optimal design of the CDCB.
Averages of the ten patients’ dose volume histogram parameters as a percentage of the conformity and uniformity indexes for the planning target volumes of left-sided breast cancer patients with irradiation of the whole breast/chest wall, the axillary (levels II and III) region, the supraclavicular field, and the internal mammary nodes by using different treatment techniques for comparison
| Technique | CB | CDCB0 | CDCB10 | CDCB15 | CDCB20 | OBDB | 5F-IMRT |
| |
|---|---|---|---|---|---|---|---|---|---|
|
|
| Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | |
| 825.838 ± 267.38 ml | CI | 0.66 ± 0.06 | 0.69 ± 0.05 | 0.69 ± 0.05 | 0.69 ± 0.05 | 0.69 ± 0.05 | 0.73 ± 0.04 | 0.66 ± 0.07 | <0.001 |
| UI | 1.06 ± 0.01 | 1.07 ± 0.01 | 1.07 ± 0.01 | 1.07 ± 0.01 | 1.07 ± 0.01 | 1.06 ± 0.01 | 1.07 ± 0.01 | <0.001 | |
| D5% | 53.35 ± 0.40 | 53.68 ± 0.35 | 53.69 ± 0.35 | 53.89 ± 0.38 | 53.73 ± 0.29 | 53.17 ± 0.41 | 53.97 ± 0.26 | <0.001 | |
| D95% | 50.22 ± 0.20 | 50.19 ± 0.14 | 50.17 ± 0.19 | 50.26 ± 0.14 | 50.16 ± 0.21 | 50.17 ± 0.21 | 50.22 ± 0.44 | 0.091 | |
| V95% | 99.10 ± 0.50 | 98.82 ± 0.45 | 98.71 ± 0.48 | 98.57 ± 0.76 | 98.69 ± 0.64 | 98.80 ± 0.42 | 98.80 ± 0.55 | <0.001 | |
| V109% | 0.35 ± 0.40 | 0.54 ± 0.52 | 0.65 ± 0.56 | 1.37 ± 1.48 | 0.83 ± 0.69 | 0.23 ±0.51 | 1.07 ± 0.91 | <0.001 | |
CB, complete block; CDCB, complete-directional complete block; CI, conformity index; Dx%, the minimum doses delivered to x% of the planning target volume; 5F-IMRT, 5-field intensity-modulated radiotherapy; OBDB, organ-base-directional block; UI, uniformity index; Vx%, the volume of the PTV receiving x% of the prescribed dose.
Data are presented as the mean ± standard deviation.
Figure 2.Axial dose distribution for the 5F-IMRT plan (A) and the HT plans: (B) OBDB, (C) CB, (D) CDCB0, (E) CDCB10, (F) CDCB15, and (G) CDCB20.
The presented p values describe the statistical relevance of the differences in V95%, conformity index and uniformity index of the planning target volume between all possible pairs of the studied planning techniques
| Parameters | PTV | ||
|---|---|---|---|
| V95% | CI | UI | |
| A | 0.097 | <0.001 | 0.017 |
| A | 0.004 | 0.003 | 0.021 |
| A | 0.004 | <0.001 | <0.001 |
| A | 0.005 | 0.002 | 0.023 |
| A | 1.000 | <0.001 | 1.000 |
| A | 1.000 | 1.000 | 0.028 |
| B | 1.000 | 1.000 | 1.000 |
| B | 1.000 | 1.000 | 0.710 |
| B | 1.000 | 1.000 | 1.000 |
| B | 1.000 | 0.014 | 0.202 |
| B | 1.000 | 1.000 | 1.000 |
| C | 1.000 | 1.000 | 1.000 |
| C | 1.000 | 1.000 | 1.000 |
| C | 1.000 | 0.001 | 0.257 |
| C | 1.000 | 1.000 | 1.000 |
| D | 1.000 | 1.000 | 1.000 |
| D | 1.000 | 0.001 | 0.030 |
| D | 1.000 | 1.000 | 1.000 |
| E | 1.000 | <0.001 | 0.100 |
| E | 1.000 | 1.000 | 1.000 |
| F | 1.000 | 0.003 | <0.001 |
A, CB; B, CDCB0; C, CDCB10; D, CDCB15; E, CDCB20; F, OBDB; G, 5F-IMRT.
Data are presented as the mean ± standard deviation.
The sum of the specific weights of each parameter in each technique for left-sided advanced breast cancer, comparison with the highest sum and a check by t-test. The specific weight for the comparison of each parameter in each technique is defined as “0”, “1” and “2” when p values were > 0.05, ≤ 0.05 and ≤ 0.001, respectively
| CB | CDCB0 | CDCB10 | CDCB15 | CDCB20 | OBDB | 5F-IMRT | ||
|---|---|---|---|---|---|---|---|---|
|
| Mean | 0 | 3 | 6 | 8 | 8 | 0 | 0 |
| V5 | 2 | 2 | 6 | 8 | 9 | 0 | 2 | |
| V10 | 0 | 1 | 4 | 5 | 4 | 0 | 1 | |
| V20 | 0 | 2 | 4 | 7 | 5 | 1 | 0 | |
| V40 | 0 | 4 | 4 | 5 | 5 | 7 | 0 | |
|
| Mean | 8 | 5 | 6 | 4 | 2 | 0 | 11 |
| V20 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | |
|
| Mean | 2 | 2 | 3 | 3 | 3 | 0 | 2 |
|
| Mean | 10 | 2 | 2 | 2 | 2 | 0 | 2 |
| V30 | 0 | 4 | 5 | 5 | 6 | 0 | 0 | |
| V40 | 0 | 4 | 6 | 4 | 7 | 0 | 0 | |
|
| Mean | 0 | 3 | 5 | 6 | 9 | 9 | 0 |
|
| 22 | 33 | 52 | 58 | 61 | 17 | 19 | |
|
| 0.06 | 0.015 | 0.211 | 0.60 | 0.003 | 0.03 |
Comparison of the planning parameters of the target and OARs for helical tomotherapy (HT) plans in this study and HT/volumetric modulated arc therapy (VMAT) plans for other studies in the literature for locoregional irradiation, including the internal mammary chain in left-sided breast cancer
| Author | Goddu[ | Caudrelier[ | Sakumi[ | Nichols[ | Tyran[ | Dumane[ | Current study (HT) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Breast/chest-wall + IMC+SCV + AX | |||||||||||
|
| 10a | 10a | 5a | 15a | 10a | 10b | 10a | |||||
|
| 50.4 | 50 | 50/45 | 50.4 | 50/46.95 | 50.4 | 50 | |||||
| (breast/LN) | (breast/LN) | |||||||||||
|
| HT | HT | VMAT | HT | VMAT | VMAT | VMAT | OBDB | CB | CDCB10 | CDCB15 | CDCB20 |
|
| ||||||||||||
| V95% (%) | 98 | 99 | 95.2/98.7/99.4 | 96.0/96.0 | 96.3 | 98.8 | 99.1 | 98.7 | 98.6 | 98.7 | ||
| (breast/clavicular/IMN) | (breast/LN) | |||||||||||
| V107% (%) | 31.1 | |||||||||||
| V109% (%) | 1.5 | 0.2 | 0.4 | 0.7 | 1.4 | 0.8 | ||||||
| D95 (Gy) | 49.8 | 49.3 | 48.89 | 50.2 | 50.2 | 50.2 | 50.3 | 50.2 | ||||
| CI | 0.56 | 0.719 | 0.778 | 0.8 (combine) | 0.73 | 0.66 | 0.69 | 0.69 | 0.69 | |||
|
| ||||||||||||
| Dmean (Gy) | 11.9 | 8.3 | 12.7 | 15.2 | 15.3 | 15.1 | 15.8 | 13.1 | 12.8 | 12.8 | ||
| V5 (%) | 73.7 | 35.4 | 74.6 | 99.3 | 96.9 | 86.7 | 84.3 | 84.1 | 56.2 | 54.8 | 54.1 | 54.0 |
| V10 (%) | 34.7 | 9.2 | 44.5 | 55.3 | 46.9 | 50.7 | 48.0 | 42.8 | 41.5 | 41.7 | ||
| V20 (%) | 17.6 | 18.9 | 29.9 | 32.3 | 25.4 | 24.7 | 26.6 | 34.3 | 25.8 | 24.8 | 24.9 | |
|
| ||||||||||||
| Dmean (Gy) | 4.2 | 6.2 | 4.0 | 4.0 | 3.6 | 6.0 | 1.1 | 1.2 | 1.4 | 1.6 | ||
|
| ||||||||||||
| Dmean (Gy) | 12.2 | 7 | 11.4 | 14.4 | 12.9 | 8.6 | 6.5 | 10.4 | 5.1 | 6.1 | 6.2 | 6.2 |
| V5 (%) | 38.3 | 90.3 | 39.0 | 88.8 | 20 | 33.2 | 33.7 | 33.9 | ||||
| V25 (%) | 0.7 | 5.5 | 5.1 | 3.6 | 5.3 | 5.4 | ||||||
| V30 (%) | 1.5 | 3.0 | 1.3 | 3.5 | 3.6 | 2.1 | 2.1 | 1.9 | ||||
| V40 (%) | 1.2 | 1.5 | 0.7 | 0.7 | 0.6 | |||||||
|
| ||||||||||||
| Dmean (Gy) | 4.3 | 4.8 | 3.1 | 1.8 | 1.5 | 3.2 | 4.2 | 4.6 | 2.8 | 2.5 | 2.5 | 2.5 |
HT, helical tomotherapy; VMAT, volumetric modulated arc therapy
a. left-sided breast cancer patients
b. five left-sided and five right-sided breast cancer patients
Comparison of dosimetric parameters in normal organs-at-risk for left-side-breast cancer patients with irradiation of the whole breast/chest wall, the axillary (levels II and III) region, the supraclavicular field, and the internal mammary nodes by using different treatment techniques
| Technique | CB | CDCB0 | CDCB10 | CDCB15 | CDCB20 | OBDB | 5F-IMRT |
| |
|---|---|---|---|---|---|---|---|---|---|
|
|
| Mean ± SD | Mean ± SD | Mean ±S D | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
|
| Mean (Gy) | 15.82 ± 1.82 | 14.03 ± 1.38 | 13.14 ± 1.41 | 12.78 ± 1.43 | 12.77 ± 1.29 | 15.07 ± 2.29 | 15.69 ± 1.54 | <0.001 |
| V5 (%) | 56.15 ± 3.95 | 58.29 ± 4.66 | 54.82 ± 4.04 | 54.10 ± 3.90 | 54.03 ± 3.95 | 84.14 ± 8.56 | 60.64 ± 5.93 | <0.001 | |
| V10 (%) | 48.02 ± 4.43 | 45.48 ± 4.26 | 42.80 ± 4.12 | 41.51 ± 4.01 | 41.67 ± 3.51 | 50.73 ± 11.71 | 43.97 ± 3.73 | <0.001 | |
| V20 (%) | 34.31 ± 4.88 | 27.80 ± 4.50 | 25.80 ± 4.41 | 24.80 ± 4.46 | 24.93 ± 4.07 | 26.56 ± 5.93 | 30.56 ± 4.02 | <0.001 | |
|
| Mean (Gy) | 1.10 ± 0.24 | 1.14 ± 0.20 | 1.21 ± 0.24 | 1.41 ± 0.24 | 1.64 ± 0.21 | 6.04 ± 0.79 | 0.87 ± 0.11 | <0.001 |
| V20 (%) | 0.15 ± 0.18 | 0.07 ± 0.06 | 0.10 ± 0.08 | 0.08 ± 0.08 | 0.10 ± 0.09 | 0.84 ± 0.77 | 0.13 ± 0.10 | <0.05 | |
|
| Mean (Gy) | 2.81 ± 1.54 | 2.81 ± 1.23 | 2.53 ± 1.33 | 2.53 ± 1.35 | 2.52 ± 1.34 | 4.56 ± 0.76 | 1.75 ± 0.99 | <0.001 |
|
| Mean (Gy) | 5.09 ± 1.30 | 5.68 ± 1.27 | 6.11 ± 1.31 | 6.20 ± 1.43 | 6.23 ± 1.40 | 10.41 ± 1.72 | 6.11 ± 1.36 | <0.001 |
| V5 (%) | 19.98 ± 5.67 | 30.23 ± 6.29 | 33.15 ± 7.20 | 33.70 ± 7.74 | 33.94 ± 7.60 | 88.81 ± 14.14 | 34.56 ± 14.45 | <0.001 | |
| V25 (%) | 5.07 ± 2.20 | 3.41 ± 1.76 | 3.59 ± 1.77 | 5.33 ± 5.0 | 5.37 ± 5.36 | 5.45 ± 2.57 | 4.72 ± 1.73 | <0.001 | |
| V30 (%) | 3.58 ± 1.67 | 2.11 ± 1.27 | 2.12 ± 1.18 | 2.14 ± 1.20 | 1.93 ± 1.16 | 3.49 ± 1.74 | 3.56 ± 1.47 | <0.001 | |
| V40 (%) | 1.47 ± 0.88 | 0.63 ± 0.57 | 0.67 ± 0.49 | 0.70 ± 0.51 | 0.55 ± 0.46 | 1.16 ± 0.72 | 1.56 ± 1.03 | <0.001 | |
|
| Mean (Gy) | 22.85 ± 6.36 | 18.44 ± 5.95 | 16.67 ± 5.52 | 16.31 ± 5.58 | 15.66 ± 5.26 | 11.83 ± 3.24 | 27.00 ± 9.63 | <0.001 |
| Maximum (Gy) | 45.49 ± 5.41 | 43.73 ± 6.56 | 40.66 ± 9.29 | 40.08 ± 10.12 | 39.70 ± 10.33 | 34.93 ± 9.07 | 47.70 ± 3.61 | <0.001 | |
CB, complete block; CDCB, complete-directional-complete block; 5F-IMRT, 5-field intensity- modulated radiotherapy; LAD, left anterior descending oronary artery; OBDB, organ-base-directional block; Vx, the volume of the organ receiving x Gy.
Data are presented as the mean ± standard deviation.
The presented p values describe the statistical relevance of the differences in dose parameters in the ipsilateral lung, the heart and the left anterior descending artery between all possible pairs of the studied planning techniques
| Parameters | Ipsilateral lung | Heart | LAD | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dmean | V5 | V10 | V20 | Dmean | V5 | V25 | V30 | V40 | Dmean | Dmax | |
| A | <0.001 | 0.105 | 0.035 | <0.001 | 0.048 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 1.000 |
| A | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.027 |
| A | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 1.000 | <0.001 | 0.003 | <0.001 | 0.027 |
| A | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 1.000 | <0.001 | <0.001 | <0.001 | 0.014 |
| A | 1.000 | <0.001 | 1.000 | 0.001 | <0.001 | <0.001 | 1.000 | 1.000 | 1.000 | <0.001 | <0.001 |
| A | 1.000 | 0.642 | 0.041 | 0.058 | 0.002 | 0.006 | 1.000 | 1.000 | 1.000 | 0.095 | 1.000 |
| B | <0.001 | <0.001 | <0.001 | 0.009 | 0.321 | 0.132 | 1.000 | 1.000 | 1.000 | 0.001 | 1.000 |
| B | <0.001 | <0.001 | <0.001 | <0.001 | 0.174 | 0.084 | 1.000 | 1.000 | 1.000 | <0.001 | 1.000 |
| B | <0.001 | <0.001 | <0.001 | <0.001 | 0.180 | 0.052 | 1.000 | 1.000 | 1.000 | <0.001 | 0.975 |
| B | 1.000 | <0.001 | 1.000 | 1.000 | <0.001 | <0.001 | 0.008 | 0.002 | 0.001 | <0.001 | 0.001 |
| B | 0.043 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 0.016 | <0.001 | 0.001 | 0.001 | 0.036 |
| C | 0.001 | 0.003 | 0.007 | <0.001 | 1.000 | 0.943 | 1.000 | 1.000 | 1.000 | 0.663 | 1.000 |
| C | 0.034 | 0.012 | 0.456 | 0.163 | 1.000 | 0.099 | 1.000 | 0.109 | 0.001 | <0.001 | 1.000 |
| C | 0.083 | <0.001 | 0.488 | 1.000 | <0.001 | <0.001 | 0.017 | 0.002 | <0.001 | 0.002 | 0.004 |
| C | <0.001 | 0.116 | 1.000 | 0.025 | 1.000 | 1.000 | <0.001 | <0.001 | <0.001 | <0.001 | 0.051 |
| D | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 0.408 | 1.000 | 0.014 | 1.000 |
| D | 0.008 | <0.001 | 0.153 | 1.000 | <0.001 | <0.001 | 1.000 | 0.003 | <0.001 | 0.011 | 0.025 |
| D | <0.001 | 0.046 | 1.000 | 0.005 | 1.000 | 1.000 | 1.000 | <0.001 | 0.001 | <0.001 | 0.061 |
| E | 0.007 | <0.001 | 0.159 | 1.000 | <0.001 | <0.001 | 1.000 | <0.001 | <0.001 | 0.041 | 0.106 |
| E | <0.001 | 0.045 | 1.000 | 0.006 | 1.000 | 1.000 | 1.000 | <0.001 | <0.001 | <0.001 | 0.041 |
| F | 1.000 | <0.001 | 1.000 | 1.000 | <0.001 | <0.001 | 1.000 | 1.000 | 0.407 | <0.001 | <0.001 |
A, CB; B, CDCB0; C, CDCB10; D, CDCB15; E, CDCB20; F, OBDB; G, 5F-IMRT.